Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis
Cancer Science · 2023-09 · 114 (9) · 3719-3727
DOI: 10.1111/cas.15894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 26.06.2023. Verfasst von Keisuke Tanaka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Lymphoproliferative Disorders. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Methotrexate (MTX)‐associated lymphoproliferative disorder (MTX‐LPD) is a troublesome problem in patients receiving MTX for rheumatoid arthritis (RA). However, its incidence, prognosis, and risk factors remain unclear. In this retrospective study, we evaluated the actual incidence, prognostic impact, and risk factors of MTX‐LPD. Of the 986 patients with RA treated with MTX, 90 patients experienced 95 new malignancies (NMs), with LPD as the most frequent in 26 patients. The cumulative LPD incidences were 1.3% and 4.7% at 5 and 10 years after MTX initiation, respectively. Among the 24 patients who discontinued MTX after developing LPD, 15 showed sustained regression, without difference in overall survival between patients with LPD and without NM. Inflammatory markers and absolute lymphocyte counts were not useful for early LPD development detection, but most of the patients with LPD had persistently elevated erythrocyte sedimentation ratios. Regarding concomitant drugs, tacrolimus increased the risk only if patients were not receiving biological disease‐modifying antirheumatic drugs (bDMARDs). bDMARDs did not increase the risk for any of the drugs or the number of classes used. The number of LPD cases was lower in patients with IL‐6A even after a long period after MTX, although with no statistically significant difference. Thus, approximately 1 in 20 patients with RA developed MTX‐LPD over the 10 years of MTX treatment, but it did not affect the survival of patients with RA. Tacrolimus increased the risk of developing LPD for certain patients and should be used with caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
ORCID-Profile: Masahide Yamamoto
Zitieren
APA
Tanaka, K., Ichikawa, A., Umezawa, N., Yamamoto, K., Yoshifuji, K., Okada, K., Nogami, A., Umezawa, Y., Nagao, T., Sakashita, C., Mori, T., Tohda, S., Koike, R., Yasuda, S., & Yamamoto, M. (2023). Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Science, 114(9), 3719-3727. https://doi.org/10.1111/cas.15894
Vancouver
Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Science. 2023;114(9):3719-3727. doi:10.1111/cas.15894
BibTeX
@article{Tanaka2023,
author = {Tanaka, Keisuke and Ichikawa, Ayako and Umezawa, Natsuka and Yamamoto, Kouhei and Yoshifuji, Kota and Okada, Keigo and Nogami, Ayako and Umezawa, Yoshihiro and Nagao, Toshikage and Sakashita, Chizuko and Mori, Takehiko and Tohda, Shuji and Koike, Ryuji and Yasuda, Shinsuke and Yamamoto, Masahide},
title = {Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {9},
pages = {3719--3727},
doi = {10.1111/cas.15894}
}
EUVIMED